Non-Fucosylated ADCC-Enhanced Anti-Human 4-1BB ligand Receptor (PF-05082566) Therapeutic Antibody (CAT#: BioBet-1401ZP) Datasheet

TNFSF9

tumor necrosis factor (ligand) superfamily, member 9

The protein encoded by this gene is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This transmembrane cytokine is a bidirectional signal transducer that acts as a ligand for TNFRSF9/4-1BB, which is a costimulatory receptor molecule in T lymphocytes. This cytokine and its receptor are involved in the antigen presentation process and in the generation of cytotoxic T cells. The receptor TNFRSF9/4-1BB is absent from resting T lymphocytes but rapidly expressed upon antigenic stimulation. The ligand encoded by this gene, TNFSF9/4-1BBL, has been shown to reactivate anergic T lymphocytes in addition to promoting T lymphocyte proliferation. This cytokine has also been shown to be required for the optimal CD8 responses in CD8 T cells. This cytokine is expressed in carcinoma cell lines, and is thought to be involved in T cell-tumor cell interaction.

CD137L; 4-1BB-L; TNFSF9; tumor necrosis factor (ligand) superfamily, member

Membrane

Diseases associated with TNFSF9 include Mouth Disease and Cone-Rod Dystrophy 2.

Its related pathways are PEDF Induced Signaling and TNF Superfamily - Human Ligand-Receptor Interactions and their Associated Functions.

Cytokines that bind to TNFRSF9. Induce the proliferation of activated peripheral blood T cells. May be involved in activation-induced cell death (AICD). It may play a role in the homologous interaction between t cells and b cells/macrophages.

1.Modification sites at neXtProt 2.Modification sites at PhosphoSitePlus

Protein Based Therapies
Monoclonal antibody (mAb)

IgG2

PF-05082566

Human

Human

PF-05082566 is a fully human IgG2 that binds to the extracellular domain of human 4-1BB with high affinity and specificity. In preclinical studies, this agonist antibody demonstrated its ability to activate NF-κB and induce downstream cytokine production, promote leukocyte proliferation, and inhibit tumor growth in a human PBMC xenograft tumor model. The mechanism of action and robust anti-tumor efficacy of PF-05082566 support its clinical development for the treatment of a broad spectrum of human malignancies.

Cancer

Cancer